secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLUS THERAPEUTICS, INC. (PSTV)
CIK:        0001095981
Form:       8-K
Filed at:   2026-08-14T20:21:11+00:00
Accession:  0001193125-26-352346
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cerenome (fka Plus Therapeutics) reports Q2 2026 net loss $9.0M, rebrands to CNSY
--------------------------------------------------------------------------------

- Q2 2026 net loss $9.0M ($1.31/sh) vs net income $5.2M ($0.62/sh) in Q2 2025, which included $6.5M derivative gain.
- Operating loss widened to $9.1M from $1.5M; grant revenue fell to $0.4M from $1.4M; cash flat at $8.6M.
- Rebranded from Plus Therapeutics to Cerenome on Aug 3, 2026; now trades as CNSY on Nasdaq.
- ReSPECT-GBM Phase 2 enrollment on track for 2026; data expected Q1 2027; ReSPECT-PBC first dosing Q3 2026.
- CNSide performed 232 tests in H1 2026; achieved 150M covered lives, CAP accreditation, and new partnerships.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1095981/000119312526352346/0001193125-26-352346-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1095981/000119312526352346/pstv-20260814.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-352346

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer